back
16.03.2012

Successful capital increase completed as planned

The MOLOGEN AG Board of Directors completed a capital increase on January 7, 2010 against cash contributions and excluding subscription rights. On the basis of an authorization granted at the Annual General Meeting, as well as the approval of the MOLOGEN AG Supervisory Board, the company placed 512,000 new ordinary bearer shares (around 5% of the total share capital) with institutional investors - each at a value of 7.00 euro. 

This amounted to an increase in capital resources totaling around 3.6 million euro, which will be specifically invested in clinical development programs for cancer medications.

The registration of the capital increase with the respective commercial register is currently under preparation. After the inclusion of this increase the share capital of MOLOGEN AG totals 10,655,348 euro.

About MOLOGEN

MOLOGEN AG, a biopharmaceutical com-pany based in Berlin, specializes in the research and development of innovative medicines based on DNA structures. Activities focus on product developments for the treatment of cancer and vaccines for serious infections.

MOLOGEN was founded in 1998 and is among the few biotechnology companies in the world with well-tolerated, DNA-based cancer treatment in the clinical development stage.
MOLOGEN AG shares are listed in the Prime Standard of Deutsche Börse (ISIN DE 0006637200).

Disclaimer concerning prognoses

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.

Capital increase 2018 from authorized capital

Further Information